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Abstract
Background: Smoking prevalence in human immunodeficiency virus (HIV) positive subjects is about three times of
that in the general population. However, whether the extremely high smoking prevalence in HIV-positive subjects
affects their lung function is unclear, particularly whether smoking decreases lung function more in HIV-positive
subjects, compared to the general population. We conducted this study to determine the association between
smoking and lung function, respiratory symptoms and diseases amongst HIV-positive subjects.
Results: Of 120 enrolled HIV-positive subjects, 119 had an acceptable spirogram. Ninety-four (79%) subjects were
men, and 96 (81%) were white. Mean (standard deviation [SD]) age was 43.4 (8.4) years. Mean (SD) of forced
expiratory volume in one second (FEV1) percent of age, gender, race and height predicted value (%FEV1) was
93.1% (15.7%). Seventy-five (63%) subjects had smoked 24.0 (18.0) pack-years. For every ten pack-years of smoking
increment, %FEV1 decreased by 2.1% (95% confidence interval [CI]: -3.6%, -0.6%), after controlling for gender, race
and restrictive lung function (R
2 = 0.210). The loss of %FEV1 in our subjects was comparable to the general
population. Compared to non-smokers, current smokers had higher odds of cough, sputum or breathlessness, after
adjusting for highly active anti-retroviral therapy (HAART) use, odds ratio OR = 4.9 (95% CI: 2.0, 11.8). However
respiratory symptom presence was similar between non-smokers and former smokers, OR = 1.0 (95% CI: 0.3, 2.8).
All four cases of COPD (chronic obstructive pulmonary disease) had smoked. Four of ten cases of restrictive lung
disease had smoked (p = 0.170), and three of five asthmatic subjects had smoked (p = 1.000).
Conclusions: Cumulative cigarette consumption was associated with worse lung function; however the loss of %
FEV1 did not accelerate in HIV-positive population compared to the general population. Current smokers had
higher odds of respiratory symptoms than non-smokers, while former smokers had the same odds of respiratory
symptoms as non-smokers. Cigarette consumption was likely associated with more COPD cases in HIV-positive
population; however more participants and longer follow up would be needed to estimate the effect of smoking
on COPD development. Effective smoking cessation strategies are required for HIV-positive subjects.
Background
In the developed world, mortality from HIV/AIDS has
decreased significantly since the introduction of highly
active anti-retroviral therapy (HAART) in 1996 [1].
Consequently, people are living with HIV/AIDS longer
than ever. In this context, chronic diseases, whether
HIV/AIDS related or not, are increasingly of concern
amongst the HIV-positive population, and for clinicians
caring for them.
Prior to 2001, annual smoking prevalence in the
Ontario Cohort Study (OCS) of HIV-positive adult sub-
jects was more than 70%, and steadily decreased to 58%
in 2007 (data unpublished), which was constantly about
three times higher than that in the Ontario general
population from 1999 to 2007 [2]. A smoking preva-
lence of 60% or more in HIV-positive subjects has been
reported in other studies [3-7]. Therefore, smoking-
related outcomes, such as lung function problems,
respiratory symptoms and lung diseases, are likely to
increase in this population. * Correspondence: cuiq2@mcmaster.ca
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smoking-related respiratory symptoms and diseases. Stu-
dies have shown that HIV-positive subjects were more
likely to have respiratory symptoms and diseases com-
pared to their HIV negative counterparts [3,8,9]. More-
over, some studies showed among HIV-positive subjects,
smokers were more likely to have respiratory problems
[8,10]. Other studies found that HIV-positive subjects
had similar lung function compared to their HIV nega-
tive counterparts [11,12], and they had similar changes
of lung function over time [13,14]. Although in the gen-
eral population, the effects of cigarette smoking on lung
function has been well demonstrated in the general
population, using different measurements of smoking
and lung function [15-21], no study has been done to
address whether cigarette smoking affects lung function
in a similar way in HIV-positive population.
Hence, the literature is unclear on the effects of smok-
ing on lung function in HIV-positive subjects, particu-
larly whether lung function decline would be greater in
HIV-positive subjects compared to the general popula-
tion. The primary objective of this study was to deter-
mine the association between smoking and lung
function amongst HIV-positive subjects. The secondary
objective was to examine the association between smok-
ing and respiratory symptoms and diseases amongst
HIV-positive subjects.
Methods
Study design, setting and participants
This was a cross-sectional study. The study protocol was
approved by the Research Ethics Board (REB) at Hamil-
ton Health Sciences/McMaster University. Consecutive
consenting HIV-positive subjects attending the regional
HIV clinic (Special Immunology Services [SIS] clinic) at
McMaster University, aged 18 years or more were eligi-
ble to take part in the study.
Study description
Our study respiratory technologist approached poten-
tially eligible subjects attending regularly scheduled clin-
ical visits at the SIS clinic. Participants provided signed
informed consent, filled out a questionnaire, and under-
went spirometry testing. The questionnaire contained
information on demography, respiratory symptoms, and
history of respiratory diseases, cigarette smoking and
other drug uses. Spirometry testing followed the stan-
dardization of spirometry testing recommended by the
American Thoracic Society (ATS) and European
Respiratory Society (ERS) [22-24]. We used a VIASYS
JAEGER FlowScreen V2.1.1 (Hoechberg, Germany). All
subjects who had forced expiratory volume in one sec-
ond (FEV1) percent of age, gender, race and height pre-
dicted value (%FEV1)l e s st h a n9 0 %w e r eg i v e nt w o
puffs of salbutamol (Ventolin, a short acting b-agonist)
and repeated spirometry to assess the change in FEV1.
Medical information such as CD4 T-lymphocyte count,
HIV viral load, date of HIV diagnosis and antiretroviral
medication was abstracted from the medical chart.
Information on history of respiratory diseases was
abstracted from the medical chart if information was
absent in the questionnaire.
Measurements
Each subject was self-classified as a non-smoker, ex-smo-
ker or current smoker. Cumulative exposure to cigarette
smoking was measured by pack-years, which was calcu-
lated by multiplying the number of packs of cigarette
smoked per day and the number of years of smoking.
Marijuana use was similarly measured as never, former
and current use. Marijuana consumption was measured
by the number of times of use per day and the number of
years of use. The primary outcome of lung function was
measured as FEV1,% F E V 1, forced vital capacity (FVC)
and FVC percent of age, gender, race and height pre-
dicted value (%FVC). All measurements were automati-
cally printed by the VIASYS JAEGER FlowScreen. Per
cent FEV1 and %FVC were calculated by dividing the
measured FEV1 and FVC by their age, gender, race and
height predicted values, which were also automatically
printed by FlowScreen. Respiratory symptoms included
cough, sputum and breathlessness. Cough was described
as current cough, productive cough and nocturnal cough.
Sputum was measured at 5 levels: no sputum, 1 tea
spoon, 1 table spoon, 2 table spoon and 1/2 cup in 24
hours. We used the Medical Research Council (MRC)
dyspnea scale to measure breathlessness. Grade 3 or
more (breathlessness walking on the level) was consid-
ered having breathlessness [25].
The diagnoses of obstructive and restrictive lung dis-
eases could be interpreted by the spirogram, however
we diagnosed these diseases based on our calculation
and the GOLD (Global initiative for chronic Obstructive
Lung Disease) guidelines. The diagnosis of obstructive
lung function was defined as pre-salbutamol FEV1/FVC
< 70% without post-salbutamol values. The diagnosis of
COPD was defined by post-bronchodilator FEV1/FVC <
70%, and COPD level was classified based on %FEV1.A
COPD case with %FEV1 ≥ 80% was classified as mild,
30% ≤ %FEV1 < 80% as moderate and %FEV1 < 30% as
severe [26]. Subjects who did not undergo post-salbuta-
mol testing could not be diagnosed as COPD by defini-
tion. For subjects whose post-salbutamol FEV1/FVC was
between 66.5% and 73.5%, the diagnosis was made by
the committee’s judgment, taking account of the pre-sal-
butamol FEV1/FVC value and clinical symptoms of
cough, sputum and breathlessness. The diagnosis of
restrictive lung function was defined as FEV1/FVC ≥
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inhalation [27,28]. Asthma was defined as reversible
FEV1, which improved more than 12% and 200 ml after
salbutamol inhalation [26]. A history of asthma was
defined as previous diagnosed or treated asthma. Nor-
mal lung function was defined as FEV1/FVC ≥ 70%, %
FEV1 ≥ 80% and %FVC ≥ 80% accordingly, by both pre-
and post-salbutamol tests. Pre-salbutamol values were
used to classify normal lung function if post-salbutamol
test was not done.
Statistical analysis
Continuous variables were reported as mean (standard
deviation [SD]) if they were normal distributed or
reported as median (first quartile [Q1], third quartile
[Q3]) if they were not normal distributed. Normality was
visually tested by P-P plots. Categorical variables were
reported as count (percent). Analysis of variance
(ANOVA) was used to compare continuous variables
among different groups and c
2 test was used for catego-
rical variables. Fisher’s exact test was adopted if the
number of cases in any cell is less than 10. Multiple
regression method was used to adjust for possible con-
founders further. Multiple linear regression was used to
model %FEV1. Multiple logistic regression model was
used for lung function, respiratory symptoms, respira-
tory diseases and subject classification. We used the cri-
terion of a = 0.20 in uni-variate regression analysis to
decide whether or not to select appropriate variables
into a multivariable regression model. Possible interac-
tion between independent variables was tested. The cri-
terion for statistical significance for multivariable
analysis was set at a = 0.05. All p-values were reported
to three digital places with those less than 0.001 were
reported as p < 0.001. All analyses were performed
using SPSS 15 (Chicago, IL).
In the multiple linear regression model, the dependent
variable was %FEV1 before salbutamol. The selected pre-
dictor was pack-years of smoking or smoking status,
depending on which variable had the smaller p value in
uni-variate analysis. Restrictive lung function was co-
variable related to %FEV1. Productive cough and age
were potential confounders based on the previous litera-
ture [17,19,20]. We examined gender and race as they
were common confounders, although previous studies
were inconclusive [18,19]. In addition, current CD4
T-lymphocytes count, current viral load, current antire-
troviral treatment and marijuana use were examined a
priori as potential confounders as well. Potential interac-
tions between independents were tested. The results
were reported as estimates of model coefficients (95%
confidence interval [CI]) and associated p-values. Results
for all subjects and for smokers (including former and
current smokers) were presented when pack-years of
smoking was the predictor variable. We examined the
residuals to assess model assumptions and goodness-of-
fit (reported using R
2).
In the multiple logistic regression model, the depen-
dent variable was lung function (normal/abnormal),
respiratory symptom (yes/no), respiratory disease (yes/
no) and subject classification (normal lung function and
no symptom/abnormal lung function or respiratory
symptom) in each analysis respectively, and the predic-
tor was smoking status. We considered the same poten-
tial confounders as we did in multiple linear regression
analysis. We selected no more than one independent
variable for each ten cases, which was considered to be
the lesser number of the outcome group. If the lesser
number of the outcome group was less than 10, logistic
regression analysis was not conducted. The results were
reported as estimates of odds ratio (OR) (95% CI) and
their p-values. Nagelkerke R square was reported to
assess the goodness-of-fit of logistic regression model.
Results
Demographic and baseline information
We recruited 120 consecutive consenting HIV positive
subjects, of whom 119 had an acceptable spirogram.
Demographic and baseline information are listed in
Table 1. Ninety-four (79%) subjects were men (one trans-
gendered individual was classified as a woman). Ninety-
six (81%) subjects were white, including 83 (88%) men
and 13 (52%) women (p < 0.001). Mean (standard devia-
tion [SD]) age was 43.4 (8.4) years. Men were 5.4 years
older than women (p = 0.004). Mean (SD) number of
years of living with HIV was 9.0 (6.6) years. One hundred
(84%) HIV-positive subjects were on antiretroviral treat-
ment at the time of study. Mean (SD) current CD4
T-lymphocytes count was 484 (274) cells/mm
3,a n d
102 (86%) of subjects had current CD4 count of
200 cells/mm
3 or more. Seventy-three (61%) subjects had
current undetectable viral load. Amongst those with
detectable viral load, median (Q1,Q 3) viral load was 907
(193, 28630), and mean (SD) of log viral load was 3.38
(1.26). No gender or race difference was found in terms
of current CD4 T-lymphocytes count or HIV viral load.
Smoking status and marijuana use
Forty-four (37%) subjects never smoked cigarettes, of whom
3 subjects currently used marijuana at the time of survey.
Twenty-three (19%) subjects had formerly smoked, of
whom 6 subjects currently used marijuana. Fifty-two (44%)
subjects currently smoked, of whom 21 subjects currently
used marijuana. Males accounted for 68% in non-smokers
and 85% in smokers respectively (p = 0.036). On average
smokers had smoked 24.0 (18.0) pack-years. Mean (SD)
pack-years of smoking was 16.8 (13.9) for former smokers
and 27.2 (18.7) for current smokers respectively (p = 0.020).
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(24%) subjects formerly used marijuana, of whom only 7
(24%) subjects used once or more per day, with mean (SD)
year of use of 8.7 (4.5) years. Thirty (25%) subjects were
currently using marijuana at the time of survey, of whom
26 (87%) subjects used once or more per day, with mean
(SD) year of use of 18.3 (9.5) years. Current users used
m a r i j u a n am o r ef r e q u e n t l y( p<0 . 0 0 1 )a n df o ral o n g e r
time (p < 0.001) than former users.
Association between lung function and smoking
Lung function by smoking status and gender was sum-
marized in Table 1. Mean (SD) of FEV1 before salbuta-
mol was 3.5 (0.8) litres. Mean (SD) of %FEV1 before
salbutamol was 93.1% (15.7%). Mean FVC before salbu-
tamol was 4.5 (1.0) litres. Forty-six (39%) HIV-positive
subjects had %FEV1 < 90% and 27 (59%) of them under-
went post salbutamol spirometry test. Mean improve-
ment was 143 (193) ml for FEV1 and 79 (263) ml for
FVC respectively.
According to our preset criterion of a = 0.2, four vari-
ables from uni-variate regression were selected to build
the multiple linear regression model: pack-years, gender,
race and restrictive lung function. For every ten pack-
years of smoking increment, %FEV1 significantly
decreased by 2.1% (95% CI: -3.6%, -0.6%), after control-
ling for gender, race and restrictive lung diseases
(p = 0.006). Moreover white subjects had 8.8% (95% CI:
Table 1 Demographic and baseline information by gender and smoking status (n = 119)
Gender Smoking status
Male
(n = 94)
Female
(n = 25)
None
(n = 44)
Former
(n = 23)
Current
(n = 52)
Total
(n = 119)
Male, n (%) - - 30 (68) 21 (91) 43 (83) 94 (79)
White, n (%) 83 (88) 13 (52) 28 (64) 19 (83) 49 (94) 96 (81)
***##
Age (years), mean (SD) 44.5 (8.3) 39.2 (7.7) 42.7 (7.7) 46.0 (8.8) 42.8 (8.8) 43.4 (8.4) **
Years of living with HIV, mean (SD) 9.6 (6.7) 6.9 (6.0) 7.3 (5.8) 10.6 (6.9) 9.7 (7.0) 9.0 (6.6)
On HAART, n (%) 86 (92) 14 (56) 35 (80) 22 (96) 43 (83) 100 (84) ***
CD4 (cells/mm
3), mean (SD) 478 (264) 505 (312) 510 (261) 402 (252) 498 (291) 484 (274)
Undetectable viral load, n (%) 62 (66) 11 (44) 25 (57) 17 (74) 31 (60) 73 (61)
Pack-years in smokers
1, mean (SD) 24.0 (17.6) 24.0 (20.7) - 16.8 (13.9) 27.2 (18.7) 24.0 (18.0)
#
Marijuana use
###
None, n (%) 42 (45) 18 (72) 34 (77) 9 (39) 17 (33) 60 (50)
Former, n (%) 24 (26) 5 (20) 7 (16) 8 (35) 14 (27) 29 (24)
Current, n (%) 28 (30) 2 (8) 3 (7) 6 (26) 21 (40) 30 (25)
FEV1 before salbutamol (litres), mean (SD) 3.8 (0.7) 2.7 (0.5) 3.48 (0.87) 3.46 (0.81) 3.62 (0.79) 3.5 (0.8)***
%FEV1 before salbutamol (%), mean (SD) 94.7 (15.8) 86.9 (14.1) 93.6 (14.0) 91.1 (18.3) 93.5 (16.1) 93.1 (15.7)*
FVC before salbutamol (litres), mean (SD) 4.9 (0.8) 3.3 (0.7) 4.26 (1.09) 4.58 (0.89) 4.76 (0.95) 4.5 (1.0)***
%FVC before salbutamol (%), mean (SD) 96.2 (12.5) 88.2 (16.7) 91.4 (13.7) 94.6 (11.7) 97.1 (14.4) 94.5 (13.8)**
Abnormal lung function
2, n (%) 16 (17) 8 (32) 8 (18%) 4 (17%) 12 (23%) 24 (20)
Asthma history, n (%) 6 (7) 7 (29) 3 (7) 3 (13) 7 (14) 13 (11)**
Asthmatic by spirometry
3, n (%) 3 (3) 2 (8) 2 (5) 1 (4) 2 (4) 5 (4)
Cough, n (%) 49 (52) 12 (48) 16 (36) 8 (35) 37 (71) 61 (51)
##
Sputum, n (%) 41 (44) 10 (40) 11 (25) 8 (35) 32 (63) 51 (43)
##
Breathlessness, n (%) 6 (6) 2 (8) 0 1 (4) 7 (14) 8 (7)
#
Any respiratory symptom
4, n (%) 51 (54) 12 (48) 16 (36) 9 (39) 38 (73) 63 (53)
##
COPD
5, n (%) 4 (4) 0 0 2 (9%) 2 (4%) 4 (3)
Restrictive lung diseases
6, n (%) 3 (3) 7 (28) 6 (14%) 1 (4%) 3 (6%) 10 (8)**
Abnormal lung function
2 or symptomatic
4, n (%) 17 (68) 54 (57) 20 (45) 11 (48) 40 (77) 71 (60)
##
P value was obtained by Analysis of variance (ANOVA) for continuous variables listed as mean (SD) and was obtained by c
2 test for categorical variables listed
as n (%). Fisher’s exact test was adopted if the number of cases in any cell was less than 10.
- Not applicable.
* p < 0.05 by gender. ** p < 0.01 by gender. *** p < 0.001 by gender.
# p < 0.05 by smoking status.
## p < 0.01 by smoking status.
### p < 0.001 by smoking status.
1Pack-year of smoking was calculated by multiplying the number of packs of cigarette smoked per day and the number of years of smoking.
2Abnormal lung
function was defined as either FEV1/FVC < 70% or %FEV1 <80% or %FVC < 80%, either pre- or post-salbutamol test.
3Asthmatic by spirometry was defined as
reversible FEV1, which improved more than 12% and 200 ml after salbutamol inhalation.
4Any respiratory symptom was defined as having cough, sputum or
breathlessness.
5COPD referred to chronic obstructive pulmonary disease, was defined as post-salbutamol FEV1/FVC < 70%.
6Restrictive lung function was defined
as FEV1/FVC ≥ 70% and %FVC < 80%, either before or after salbutamol inhalation.
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trolling for pack-years, gender and restrictive lung dis-
eases (p = 0.023). Gender did not affect %FEV1
significantly (p = 0.640). No interaction between inde-
pendents was found. The point estimate of b coefficient
of -2.0% (95% CI: -4.2%, 0.2%) was similar when non-
smokers were excluded, with wider 95% CI (p = 0.077).
The point estimate of pack-years did not change when
the association was not adjusted for gender. Coefficients
and 95% CIs of each variable versus %FEV1 in different
populations were summarized in Table 2.
Among 24 (20%) subjects who had abnormal lung
function, there were 8 non-smokers, 4 former smokers
and 12 current smokers respectively (p = 0.782) (Table
1). According to preset criterion of a =0 . 2 ,s m o k i n g
status was not selected into multiple logistic regression
model for abnormal lung function.
Association between respiratory symptoms and smoking
Cough
Sixty-one (51%) subjects coughed, including 16 (36%)
non-smokers, 8 (35%) former smokers and 37 (71%)
current smokers (p = 0.001) (Table 1). Compared to
non-smokers, current smokers had higher odds of
cough, OR = 4.3 (95% CI: 1.5, 12.0) after controlling for
marijuana use, race, current HAART status and current
viral load (p = 0.005). For former smokers the OR of 0.8
(95% CI: 0.3, 2.6) was not statistically significant com-
pared to non-smokers (p = 0.753). No interaction was
found. Moreover, subjects who were on HAART had
higher odds of cough (OR = 5.5, 95% CI: 1.4, 21.5, p =
0.014), and subjects who had suppressed viral load had
lower odds of cough (OR = 0.3, 95% CI: 0.1, 0.9, p =
0.025). The results are presented in Table 3.
Sputum
Fifty-one (43%) subjects produced sputum, including 11
(25%) non-smokers, 8 (35%) former smokers and 32
(63%) current smokers (p = 0.001) (Table 1). Compared
to non-smokers, current smokers had higher odds of
sputum, OR = 5.0 (95% CI: 1.9, 13.3) after controlling
for marijuana use (p = 0.001). For former smokers the
OR of 1.7 (95% CI: 0.5, 5.3) was not significant com-
pared to non-smokers (p = 0.382). No interaction
existed. The results are presented in Table 3.
Breathlessness
Eight subjects (7%) had breathlessness (Table 1). All of
them were smokers including 1 former smoker and 7
current smokers (p = 0.027), however we could not
compute the OR because of 0 cases in the reference
(non-smoker) group, nor could we use logistic regres-
sion to estimate the risk factors further.
Any symptom
In terms of three respiratory symptoms (cough, sputum
and breathlessness), 63 (53%) subjects had at least one
respiratory symptom, including 16 (36%) non-smokers,
9 (39%) former smokers and 38 (73%) current smokers
(p = 0.001) (Table 1). Compared to non-smokers, cur-
rent smokers were 4.9 (95% CI of OR: 2.0, 11.8) times
more likely to have at least one symptom, after control-
ling for current HAART status (p < 0.001). For former
smokers the OR was 1.0 (95% CI: 0.3, 2.8) compared to
non-smokers (p = 0.969). No interaction existed. The
results are presented in Table 3 and Figure 1.
Association between respiratory diseases and smoking
COPD
Three (3%) subjects were diagnosed with COPD origin-
ally. In addition, one subject with borderline lung func-
tion was diagnosed with COPD by the committee. All
these 4 cases of COPD were moderate in severity
according to GOLD guidelines, and asthma co-existed
in 2 COPD cases. All of them were white men, mean
(SD) age was 49.8 (7.3), ranging from 43 to 57 years old.
All were smokers with mean (SD) pack-years of 29.5
(13.8), however COPD was not associated with ever
smoking status (p = 0.295), probably due to the small
number of cases. The OR could not be calculated
because of zero case in non-smokers. Notably 14 (12%)
Table 2 b Coefficients and 95% CIs of each variable versus %FEV1 by model and population
In all the subjects In smokers
Model 1
# Model 2
## Model 1
# Model 2
##
Per 10 pack-years -0.021 (-0.036, -0.006)** -0.021 (-0.036, -0.006)** -0.020 (-0.042, 0.002) -0.020 (-0.042, 0.002)
Male 0.017 (-0.054, 0.088) Not assessed -0.034 (-0.144, 0.077) Not assessed
White 0.088 (0.012, 0.163)* 0.093 (0.020, 0.165)* 0.050 (-0.086, 0.187) 0.052 (-0.083, 0.188)
Restrictive lung diseases -0.167 (-0.270, -0.065)** -0.174 (-0.272, -0.077)** -0.133 (-0.309, 0.042) -0.121 (-0.290, 0.049)
All the results were from the multiple linear regression analysis, in which the dependent variable was %FEV1. Pack-year of smoking was calculated by multiplying
the number of packs of cigarette smoked per day and the number of years of smoking. Restrictive lung function was defined as FEV1/FVC ≥ 70% and %FVC <
80%, either before or after salbutamol inhalation.
# In model 1, the association between %FEV1 and pack-years of smoking was adjusted for by gender, race and restrictive lung diseases. R
2 = 0.210 in all the
subjects and R
2 = 0.084 in smokers.
## In model 2, the association between %FEV1 and pack-years of smoking was adjusted for by race and restrictive lung diseases. R
2 = 0.209 in all the subjects
and R
2 = 0.080 in smokers.
*p<0 . 0 5f o rb coefficient. **p < 0.01 for b coefficient.
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spirometry testing, however only 5 (38%) of them
underwent post salbutamol testing. Therefore we could
not confirm the other 9 potential COPD subjects.
Among 14 subjects with pre-salbutamol obstructive lung
function, there were 2 non-smokers, 3 former smokers
and 9 current smokers. Although smokers had 4.0 times
the odds of pre-salbutamol obstructive lung function,
this crude OR was not significant (p = 0.079) and its
95% CI (0.9, 18.8) was very wide. COPD results are pre-
sented in Table 1 and Figure 1.
Restrictive lung function
Ten (8%) subjects had restrictive lung function. Mean
(SD) age was 42.5 (7.0), ranged from 34 to 56 years old.
Seven (70%) of them were women, including 6 black
women. Amongst 10 subjects with restrictive lung func-
tion, there were 4 smokers including 1 former smoker
and 3 current smokers (p = 0.170) (Table 1). Multiple
logistic regression analysis was not conducted because
there were ten cases of restrictive lung function only.
Results are also presented in Figure 1.
Asthma
Thirteen (11%) subjects had a history of asthma, which
was not associated with smoking status (p = 0.553)
(Table 1). Only 5 (38%) of them underwent post-salbu-
tamol testing and 2 subjects were asthmatic at the time
of study. In addition, among 106 subjects without an
asthma history, 3 (3%) were asthmatic. In total 5 sub-
jects were asthmatic at the time of study, which was not
associated with smoking status (p = 0.985). In total 16
(13%) subjects were asthmatic or had an asthma history,
which was not associated with smoking status (p =
0.551). A history of asthma and spirometry diagnosed
asthma are also presented in Figure 1.
Respiratory diseases history
A history of bronchitis was present in 38 (32%) subjects,
pneumonia in 46 (39%) subjects, tuberculosis in 5 (4%)
subjects, emphysema in 1 (1%) subject and asthma in 13
(11%) subjects. Former smokers had 3.7 times the odds
of a history of bronchitis than non-smokers (95% CI:
1.1, 12.5), after controlling for race and HAART use
(p = 0.038), while the OR of 1.5 (95% CI: 0.6, 4.1) for
current smokers was insignificant (p = 0.421). Moreover,
white subjects had 12.4 (95% CI: 1.5, 101.7) times the
odds of a history of bronchitis compared to non-white
subjects (p = 0.019). A history of other respiratory dis-
eases was not associated with smoking status.
Subject classifications and their association with smoking
The exclusive subject categories based on lung func-
tion, respiratory symptoms, COPD and restrictive lung
disease are shown in the study flow chart (Figure 1).
The category of ‘normal lung function without symp-
tom’ represented subjects who had normal lung func-
tion and did not have any respiratory symptoms.
Forty-eight (40%) subjects were in this category,
including 2 subjects with a history of asthma. In this
category there were 24 non-smokers, 12 ex-smokers
and 12 current smokers, accounting for 55%, 52% and
23% in each smoking category respectively (p = 0.004)
(Table 1). All potential confounders had p > 0.2 in
uni-variate analysis except smoking status. Comparing
to non-smokers, current smokers were 0.3 times less
likely to be classified as ‘normal lung function without
symptom’, OR = 0.3 (95% CI: 0.1, 0.6) (p = 0.002). The
OR of 0.9 (95% CI: 0.3, 2.5) was not significant for for-
mer smokers (p = 0.853). Results are listed in Table 3
and Figure 1.
Table 3 ORs and 95% CIs of each variable versus respiratory symptoms, respiratory diseases and subject classification
Cough
a Sputum
b Any respiratory symptom
c Normal lung function without symptom
d
Former smoker 0.8 (0.3, 2.6) 1.7 (0.5, 5.3) 1.0 (0.3, 2.8) 0.9 (0.3, 2.5)
Current smoker 4.3 (1.5, 12.0)** 5.0 (1.9, 13.3) ** 4.9 (2.0, 11.8) *** 0.3 (0.1, 0.6) **
Former marijuana user 0.7 (0.3, 2.1) 0.6 (0.2, 1.7) - -
Current marijuana user 1.5 (0.5, 4.6) 1.3 (0.5, 3.5) - -
White 1.1 (0.4, 3.5) - - -
On HAART 5.5 (1.4, 21.5)* - 2.7 (0.9, 8.1) -
Undetectable viral load 0.3 (0.1, 0.9)* - - -
All the results were from multiple logistic regression analysis. Non-smoker group was the reference group in all the analysis. Reference group for other variables
was non-marijuana user, non-white subject, subject who was not on HAART and subject who had detectable viral load respectively.
- The variable had p > 0.2 in uni-variate analysis and was not selected into multiple logistic regression analysis.
*p < 0.05 for the OR. ** p < 0.01 for the OR. *** p < 0.001 for the OR.
a Subject having no cough was reference group. Nagelkerke R
2 = 0.252.
bSubject having no sputum was reference group. Nagelkerke R
2 = 0.177.
cSubject having no respiratory symptom at all was reference group. Respiratory symptom was defined as cough, sputum or breathlessness. Nagelkerke R
2 =
0.194.
d Subject having either abnormal lung function or any respiratory symptom was reference group. Abnormal lung function was defined as either FEV1/FVC < 70%
or %FEV1<80% or %FVC < 80%, either pre- or post-salbutamol test. Nagelkerke R
2 = 0.128.
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We did not find excessive decline of %FEV1 in HIV-
positive subjects compared with published reference
ranges for the general population. In our study ten
pack-years %FEV1 change was -2.1% (95% CI: -3.6%,
-0.6%). In a population-based cross-sectional study, the
%FEV1 before salbutamol in 2050 white people
decreased by 0.29% (95% CI: -0.33%, -0.25%) for every
one pack-years increment [17], which would equal an %
FEV1 change of -2.9% (95% CI -3.3%, -2.5%) per ten
pack-years. The findings in our study are comparable to
that in the general population. Similar results were
reported in previous studies, where HIV-positive sub-
jects had similar loss of lung function as their HIV-
negative counterparts [13,14], which did not support the
hypothesis that lung function decline is greater in the
HIV-positive population.
We should keep in mind that our study was cross-sec-
tional and the effect of smoking we found might not
apply to a cohort study [16,29]. In a cross-sectional
Excluded 1 
unacceptable spirogram
Pre-salbutamol only 
n=12
Post-salbutamol 
n=12
Pre-salbutamol
No symptom n=48
(2 history of asthma) 
Symptom only n=47 
(8 history of asthma 
and 3 asthmatic)
Restrictive n=2 
(1 symptomatic)
Obstructive n=9 
(all symptomatic and 
1 history of asthma)
COPD n=4 
(2 symptomatic 
and 2 asthmatic)
Restrictive n=8 
(3 symptomatic and 
2 history of asthma)
Neither obstructive 
nor restrictive n=1 
(symptomatic)
All n=120
Analyzed 
n=119
Normal lung function n=95 
(15 by post-salbutamol)
Abnormal lung function n=24
Figure 1 Study flow chart and subject classifications. Normal lung function was defined by FEV1/FVC ≥ 70% and %FEV1 ≥ 80% and %FVC ≥
80%, by both pre- and post-salbutamol tests. Pre-salbutamol values were used to classify normal lung function if post-salbutamol test was not
done. Abnormal lung function was defined by either FEV1/FVC < 70% or %FEV1 < 80% or %FVC < 80%, either pre- or post-salbutamol test.
Symptomatic was defined as having cough, sputum or breathlessness. Obstructive lung function was classified as pre-salbutamol FEV1/FVC <
70% without post-salbutamol values. COPD was defined as post-salbutamol FEV1/FVC < 70%. Restrictive lung function was defined by FEV1/FVC
≥ 70% and %FVC < 80%, either before or after salbutamol inhalation. Asthma was defined as reversible FEV1, which improved more than 12%
and 200 ml after salbutamol inhalation.
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FEV1decreased by 7.4 ml (95% CI: 6.4, 8.4) in a typical
male (173 cm tall) and by 4.4 ml (95% CI: 3.2, 5.6) in a
typical female (161 cm tall) respectively [16]. While in
this same population after 6-year follow up, the longitu-
dinal analysis showed that among smokers, for every
one pack/day of cigarette smoking, the rate of FEV1
decrease was 12.6 ml/year (95% CI: 9.7, 15.5) for men
and 7.2 ml/year (95% CI: 4.8, 9.6) for women [29].
Therefore we should not extrapolate the same coeffi-
cient of pack-years of smoking found in a cross-sec-
tional study to a prospective cohort study. In other
words, we could not predict an HIV-positive smoker
would decrease %FEV1 by 2.1% if s/he continued smok-
ing for another 10 pack-years.
In the multiple regression model for %FEV1, the coef-
ficient of gender was not significant (p = 0.640), and the
point estimate of coefficient of pack-years did not
change regardless of adjustment for gender, suggesting
that gender did not affect %FEV1 in this HIV positive
population. Similar results were reported in a meta-
regression analysis where eight large population-based
cross-sectional studies were synthesized: neither gender
nor race affected the association of cigarette smoking
with lung function measured by residual FEV1 (observed
- expected value) [18]. However, other population-based
studies showed that smoking affected the annual
decrease of FEV1 significantly more in males than in
females [16,19,29]. Further study is needed to compare
the result in our study to the general population.
Our study found that current smokers had signifi-
cantly higher odds of cough and sputum than either
non-smokers or former smokers, while the difference
between non-smokers and former smokers was not sig-
nificant, after controlling for possible confounders. The
findings were consistent with other studies [8,30,31].
Therefore, effective smoking cessation projects would
help HIV-positive smokers to have less cough and spu-
tum. Moreover, the prevalence of smoking in our study
was 2.4 (95% CI: 2.0, 3.0) times higher than that in
Ontario general population in 2007 [2], which reinforced
the need for smoking cessation programmes in the HIV-
positive population. Fortunately 20 (38%) of current
smokers were trying to quit smoking at the time of
study. Fifteen (65%) former smokers quit smoking suc-
cessfully without medication or counselling, implying
insufficient involvement of health care providers in
terms of helping smokers quit. Further, our study
showed an association of smoking with childhood
household smoking environment (p = 0.023): current
smokers accounted for 7 (24%) of those subjects whose
parents did not smoke, 12 (33%) if the father smoked, 6
(60%) if the mother smoked and 27 (63%) if both par-
ents smoked. Therefore, an effective smoking cessation
program should target not only current smokers, but
also health professionals and families.
Marijuana use was evaluated in our study when the
effect of smoking was estimated. Marijuana use might
be associated with respiratory symptoms such as cough
and sputum production. We found current marijuana
users tended to use more frequently and for longer time
than former users, however we did not know how many
joints a subject consumed each time. More measure-
ment of cumulative marijuana consumption might be
more helpful to further examine the effect of marijuana
use more deeply.
Subjects in our study represented the source popula-
tion at the SIS clinic fairly well. Only five patients
refused participating. In a clinical database of our study
population (data unpublished), mean (SD) age among
726 active patients was 43.0 (10.5) years old in 2007,
males accounted for 68% (95% CI: 65%, 72%), and
smoking prevalence was 48% (95% CI: 44%, 53%). Com-
pared to this clinical database, the subjects in our study
was comparable in terms of age (p = 0.718) and smok-
ing prevalence (p = 0.365), however we recruited a
slightly greater proportion of males in our study (rate
ratio RR = 1.1, 95% CI: 1.0, 1.3). Notably the smoking
prevalence of 44% (95% CI: 35%, 53%) in our study was
significantly lower than 58% (95% CI: 55%, 61%), the
lowest smoking prevalence in OCS over time in 2007
(data unpublished). As OCS was a province-wide study,
we considered it the best resource to assess smoking
prevalence in Ontario HIV-positive population, although
the subjects in OCS might not represent the whole HIV
positive population in Ontario due to voluntary partici-
pation. Nevertheless the representativeness of our study
subjects was limited to our clinic only.
Since we only detected four cases of COPD, we had
low power to examine the effect of smoking on COPD.
Nevertheless all four COPD cases were smokers, and
smokers had a crude OR of 4.0 (95% CI: 0.9, 18.8) of
pre-salbutamol obstructive lung function compared to
non-smokers in our study. In a prospective observa-
tional study with 867 HIV-positive veterans, either for-
mer or current smokers were 5.3 times more likely to
develop COPD than non-smokers (95% CI was 1.5 to
18.0 for former smokers and 1.6 to 17.0 for current
smokers) [10]. Our study was comparable with these
results, albeit underpowered to detect statistically signifi-
cant difference due to the small number of COPD cases.
We likely would have captured more cases of COPD,
if all the subjects with pre-salbutamol obstructive lung
function had undergone post-salbutamol testing.
According to our preset criteria, all subjects with %FEV1
< 90% should undergo post salbutamol test, which
should have included 46 subjects. However only 27
(59%) of these subjects agreed to salbutamol inhalation
Cui et al. AIDS Research and Therapy 2010, 7:6
http://www.aidsrestherapy.com/content/7/1/6
Page 8 of 10followed by repeat spirometry, primarily due to time
limitations. As a result, amongst 14 subjects whose spir-
ogram suggested COPD by pre-salbutamol test, 9 (64%)
subjects did not undergo post-salbutamol test and could
not be confirmed. We might expect 5 to 6 more cases
of COPD in our study. In a prospective observational
study the prevalence of COPD in 1014 HIV positive
veterans was 10% by ICD-9 codes and 15% by self
report respectively [9]. Comparing this HIV-positive
veteran population to our study population, the median
age of study population was 50 versus 44.0 years old,
the median age of COPD cases was 52 (by ICD-9 codes,
51 by self report) versus 49.5 years old. COPD usually is
often diagnosed in patients 50 years or older, and longer
follow up will be needed to observe development of
additional COPD cases.
Conclusions
In conclusion, we found cigarette smoking affected HIV
infected subjects similarly to estimates of its effect in
the general population. Cumulative cigarette consump-
tion was associated with worse lung function and higher
odds of respiratory symptoms. However the loss of %
FEV1 did not accelerate in HIV-positive population
compared to the general population. Current smokers
were at significant higher odds to present respiratory
symptoms compared to non-smokers, but former smo-
kers were at the similar risk compared to non-smokers.
Although all four COPD cases had smoked, we could
not evaluate the effect of smoking on COPD due to
small number of cases. More participants and longer fol-
low up would be needed to estimate the effect of smok-
ing on COPD development. Our study highlighted the
importance of smoking cessation in the HIV-positive
population in terms of improving lung function and
reducing respiratory symptoms, and may prevent the
development of COPD.
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